– UK, Liverpool – Redx (AIM:REDX), the drug discovery and development company, is pleased to announce the appointment of David Lawrence as Non-Executive Director. David succeeds Derek Lindsay, who is stepping down from the Board, with both changes taking immediate effect. Derek will remain with the Company as Chief Operating Officer.

David, aged 53, has over 25 years’ experience in the biotech and pharmaceutical industries. He has a strong track record in strategy, business development and commercial management, including working with a number of investors, biotech start-ups and SMEs.

David is currently a Non-Executive Director at Synpromics Ltd, a synthetic biology company that he co-founded. Additionally he acts as an advisor in the technology sector. In 2014-2015 he was CEO of Sentintext Therapeutics, a biotech focussed on the development of vaccines for enterviruses. He was also a director of QSpine Limited, which designs, manufactures and distributes surgical spine medical devices.

Between 2010-2014, he was Chairman of Ambicare Health Limited, where he oversaw the company’s progression from R&D into revenue generation. Before that, as CEO of Tayside Flow Technologies Ltd, he led Tayside’s strategic and commercial transformation into a revenue generating company.

David also worked at a number of major pharmaceutical companies, including Chiron Vaccines, now part of Novartis, Acambis plc, now part of Sanofi, where he was CFO, and he spent the first 13 years of his career at GlaxoSmithKline, latterly as Vice President of R&D Financial Management.

Neil Murray, Chief Executive of Redx, commented: “We are delighted to announce the appointment of David as Non-Executive Director and would like to welcome him to the Board. We are confident that his extensive commercial and financial experience in the biotech and pharmaceutical industries will benefit Redx.

The Board would also like to place on record its thanks to Derek Lindsay, who as co-founder has made an enormous contribution to the Company and to the Board. We look forward to continuing to work with Derek in his role as COO.”

About Redx Pharma Plc

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

here, the original post =>

Comments are closed.